Literature DB >> 20065792

Update on frontotemporal dementia.

Zoe Arvanitakis1.   

Abstract

BACKGROUND: Frontotemporal dementia has recently been recognized as a common cause of young-onset dementia.
OBJECTIVE: To review the current approach to the clinical evaluation, understanding of pathophysiology, and management of frontotemporal dementia.
RESULTS: Two main clinical presentations are: (1) behavioral, with impulsive behaviors and disinhibition, change in personality such as apathy and indifference, and poor judgment, and (2) language, with a nonfluent aphasia with anomia (primary progressive aphasia), or a fluent aphasia with early loss of word meaning (semantic dementia). The differential diagnosis includes other neurodegenerative dementias, vascular and other conditions affecting the brain, and psychiatric diseases. Investigations, including neuropsychological testing, and structural and functional brain imaging, may help support the diagnosis. Recent advances in understanding the pathophysiology have suggested that most cases have underlying ubiquitin-positive inclusions, whereas some have tau-positive inclusions. Genetic mutations, particularly on chromosome 17 in the tau or progranulin genes, have been identified. Management includes a trial of symptomatic medications and a multifaceted approach, including environmental modification and long-term care planning.
CONCLUSION: Medical researchers studying frontotemporal dementia aim to identify disease-modifying drugs and, ultimately, a cure for this devastating disease.

Entities:  

Mesh:

Year:  2010        PMID: 20065792      PMCID: PMC3632348          DOI: 10.1097/NRL.0b013e3181b1d5c6

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  73 in total

Review 1.  Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies.

Authors:  Adam L Boxer; Bradley F Boeve
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Oct-Dec       Impact factor: 2.703

2.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

3.  Rate of cognitive change measured by neuropsychologic test performance in 3 distinct dementia syndromes.

Authors:  Alissa H Wicklund; Alfred Rademaker; Nancy Johnson; Bing Bing Weitner; Sandra Weintraub
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Oct-Dec       Impact factor: 2.703

4.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons.

Authors:  Julie A Schneider; Zoe Arvanitakis; Woojeong Bang; David A Bennett
Journal:  Neurology       Date:  2007-06-13       Impact factor: 9.910

5.  Screening for frontotemporal dementias and Alzheimer's disease with the Philadelphia Brief Assessment of Cognition: a preliminary analysis.

Authors:  David J Libon; Lauren Massimo; Peachie Moore; H Branch Coslett; Anjan Chatterjee; Geoffrey K Aguirre; Aaron Rice; Luisa Vesely; Murray Grossman
Journal:  Dement Geriatr Cogn Disord       Date:  2007-10-30       Impact factor: 2.959

6.  Galantamine in frontotemporal dementia and primary progressive aphasia.

Authors:  A Kertesz; D Morlog; M Light; M Blair; W Davidson; S Jesso; R Brashear
Journal:  Dement Geriatr Cogn Disord       Date:  2008-01-14       Impact factor: 2.959

7.  Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.

Authors:  Elisabeth Kapaki; George P Paraskevas; Sokratis G Papageorgiou; Anastasios Bonakis; Nikolaos Kalfakis; Ioannis Zalonis; Demetris Vassilopoulos
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jan-Mar       Impact factor: 2.703

8.  Spontaneous social behaviors discriminate behavioral dementias from psychiatric disorders and other dementias.

Authors:  Katherine P Rankin; Wendy Santos-Modesitt; Joel H Kramer; Danijela Pavlic; Victoria Beckman; Bruce L Miller
Journal:  J Clin Psychiatry       Date:  2008-01       Impact factor: 4.384

9.  Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study.

Authors:  Isabelle Le Ber; Agnès Camuzat; Didier Hannequin; Florence Pasquier; Eric Guedj; Anne Rovelet-Lecrux; Valérie Hahn-Barma; Julie van der Zee; Fabienne Clot; Serge Bakchine; Michèle Puel; Mustapha Ghanim; Lucette Lacomblez; Jacqueline Mikol; Vincent Deramecourt; Pascal Lejeune; Vincent de la Sayette; Serge Belliard; Martine Vercelletto; Christian Meyrignac; Christine Van Broeckhoven; Jean-Charles Lambert; Patrice Verpillat; Dominique Campion; Marie-Odile Habert; Bruno Dubois; Alexis Brice
Journal:  Brain       Date:  2008-02-01       Impact factor: 13.501

10.  Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations.

Authors:  Stuart M Pickering-Brown; Sara Rollinson; Daniel Du Plessis; Karen E Morrison; Anoop Varma; Anna M T Richardson; David Neary; Julie S Snowden; David M A Mann
Journal:  Brain       Date:  2008-01-11       Impact factor: 13.501

View more
  17 in total

Review 1.  Autophagy as a common pathway in amyotrophic lateral sclerosis.

Authors:  Dao K H Nguyen; Ravi Thombre; Jiou Wang
Journal:  Neurosci Lett       Date:  2018-04-04       Impact factor: 3.046

2.  Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.

Authors:  Carlos Cruchaga; Caroline Graff; Huei-Hsin Chiang; Jun Wang; Anthony L Hinrichs; Noah Spiegel; Sarah Bertelsen; Kevin Mayo; Joanne B Norton; John C Morris; Alison Goate
Journal:  Arch Neurol       Date:  2011-01-10

Review 3.  PET/CT in diagnosis of dementia.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

Review 4.  Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.

Authors:  Gregory A Jicha
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

5.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

6.  Consumption of pharmaceuticals in primary non-Alzheimer's degenerative dementias : a cross-sectional study by the Registry of Dementias of Girona (ReDeGi).

Authors:  Secundino López-Pousa; Oriol Turró-Garriga; Laia Calvó-Perxas; Olga Carmona; Jordi Gich; Elisabet Alsina; Fabià Màrquez; Marta Viñas; Josefa Turbau; Joan Vilalta-Franch; Anna Maria Roig; Josep Garre-Olmo
Journal:  Drugs Aging       Date:  2012-09       Impact factor: 3.923

Review 7.  Review: disruption of the postsynaptic density in Alzheimer's disease and other neurodegenerative dementias.

Authors:  Yuesong Gong; Carol F Lippa
Journal:  Am J Alzheimers Dis Other Demen       Date:  2010-09-21       Impact factor: 2.035

Review 8.  Parkinsonian syndrome in familial frontotemporal dementia.

Authors:  Joanna Siuda; Shinsuke Fujioka; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2014-06-13       Impact factor: 4.891

9.  Managing differences: care of the person with frontotemporal degeneration.

Authors:  Geri R Hall; Jill Shapira; Maribeth Gallagher; Sharon S Denny
Journal:  J Gerontol Nurs       Date:  2013-02-11       Impact factor: 1.254

Review 10.  Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.

Authors:  Rachel E Seltman; Brandy R Matthews
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.